Literature DB >> 32039342

Dose modification for safe treatment of a compound complex heterozygous DPYD variant carrier with 5-fluorouracil.

Shikshya Shrestha1, Erin E Tapper1, Colbren Scout Trogstad-Isaacson1, Timothy J Hobday2,3, Steven M Offer1,2,4, Robert B Diasio1,2,4.   

Abstract

Entities:  

Year:  2018        PMID： 32039342      PMCID： PMC7006951          DOI： 10.1200/po.18.00179

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  12 in total

1.  Quantitative Contribution of rs75017182 to Dihydropyrimidine Dehydrogenase mRNA Splicing and Enzyme Activity.

Authors:  Q Nie; S Shrestha; E E Tapper; C S Trogstad-Isaacson; K J Bouchonville; A M Lee; R Wu; C R Jerde; Z Wang; P A Kubica; S M Offer; R B Diasio
Journal:  Clin Pharmacol Ther       Date:  2017-05-26       Impact factor: 6.875

2.  DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).

Authors:  Adam M Lee; Qian Shi; Emily Pavey; Steven R Alberts; Daniel J Sargent; Frank A Sinicrope; Jeffrey L Berenberg; Richard M Goldberg; Robert B Diasio
Journal:  J Natl Cancer Inst       Date:  2014-11-07       Impact factor: 13.506

3.  Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5-Fluorouracil Sensitivity in an East African Population.

Authors:  T Elraiyah; C R Jerde; S Shrestha; R Wu; Q Nie; N H Giama; V Sarangi; L R Roberts; S M Offer; R B Diasio
Journal:  Clin Pharmacol Ther       Date:  2016-11-26       Impact factor: 6.875

4.  DPYD*2A mutation: the most common mutation associated with DPD deficiency.

Authors:  M W Saif; Hany Ezzeldin; Katisha Vance; Sandra Sellers; Robert B Diasio
Journal:  Cancer Chemother Pharmacol       Date:  2006-12-13       Impact factor: 3.333

5.  Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity.

Authors:  Steven M Offer; Natalie J Wegner; Croix Fossum; Kangsheng Wang; Robert B Diasio
Journal:  Cancer Res       Date:  2013-01-17       Impact factor: 12.701

6.  Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance).

Authors:  Adam M Lee; Qian Shi; Steven R Alberts; Daniel J Sargent; Frank A Sinicrope; Jeffrey L Berenberg; Axel Grothey; Blase Polite; Emily Chan; Sharlene Gill; Morton S Kahlenberg; Suresh G Nair; Anthony F Shields; Richard M Goldberg; Robert B Diasio
Journal:  Pharmacogenet Genomics       Date:  2016-03       Impact factor: 2.089

7.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.

Authors:  Ursula Amstutz; Linda M Henricks; Steven M Offer; Julia Barbarino; Jan H M Schellens; Jesse J Swen; Teri E Klein; Howard L McLeod; Kelly E Caudle; Robert B Diasio; Matthias Schwab
Journal:  Clin Pharmacol Ther       Date:  2017-11-20       Impact factor: 6.875

Review 8.  Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.

Authors:  Didier Meulendijks; Linda M Henricks; Gabe S Sonke; Maarten J Deenen; Tanja K Froehlich; Ursula Amstutz; Carlo R Largiadèr; Barbara A Jennings; Anthony M Marinaki; Jeremy D Sanderson; Zdenek Kleibl; Petra Kleiblova; Matthias Schwab; Ulrich M Zanger; Claire Palles; Ian Tomlinson; Eva Gross; André B P van Kuilenburg; Cornelis J A Punt; Miriam Koopman; Jos H Beijnen; Annemieke Cats; Jan H M Schellens
Journal:  Lancet Oncol       Date:  2015-10-23       Impact factor: 41.316

9.  Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity.

Authors:  Steven M Offer; Croix C Fossum; Natalie J Wegner; Alexander J Stuflesser; Gabriel L Butterfield; Robert B Diasio
Journal:  Cancer Res       Date:  2014-03-19       Impact factor: 12.701

10.  A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity.

Authors:  S M Offer; A M Lee; L K Mattison; C Fossum; N J Wegner; R B Diasio
Journal:  Clin Pharmacol Ther       Date:  2013-04-03       Impact factor: 6.875
View more
  2 in total

1.  Severe Capecitabine Toxicity Associated With a Rare DPYD Variant Identified Through Whole-Genome Sequencing.

Authors:  Reynold C Ly; Remington E Schmidt; Patrick J Kiel; Victoria M Pratt; Bryan P Schneider; Milan Radovich; Steven M Offer; Robert B Diasio; Todd C Skaar
Journal:  JCO Precis Oncol       Date:  2020-06-12

Review 2.  Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy.

Authors:  Robert B Diasio; Steven M Offer
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.